Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

Researchers at the Indian Institute of Technology Madras (IIT Madras) have released the world’s most detailed 3D atlas of the human brainstem.

Called ANCHOR (Atlas of Neurochemical Characterization of the Human Brainstem with 3D Reconstruction), the atlas was developed using a high-throughput brain imaging and computing platform that transforms whole human brains into 3D cell-resolution atlases.

It provides comprehensive multi-modal 3D maps of the human brainstem across the lifespan, covering the prenatal period, childhood, and adulthood.

The atlas includes more than 200 brainstem nuclei and fiber tracts reconstructed from hundreds of serial sections. To identify distinct neurochemical cell types, researchers overlaid eight complementary immunostains across more than 500 sections, enabling detailed mapping.

Developed by the Sudha Gopalakrishnan Brain Centre (SGBC) at IIT Madras, ANCHOR has been made publicly available to researchers, clinicians, and patients worldwide.

“This is a significant accomplishment in the field of neurobiology. This is a multimodal framework integrating MRI, histology, and detailed chemo-architecture. It will be the most detailed and comprehensive maps of the human brainstem, and made available publicly in digital form. These maps will help in identifying specific cell populations affected in brain stem lesions, which could be critical for clinical applications,” said Prof. Ajay Kumar Sood, Principal Scientific Adviser to the Government of India, during the 3rd BRICS Neuroscience Symposium 2026.

Prof. Mohanasankar Sivaprakasam, Head of SGBC, IIT Madras, said the atlas uses a multimodal image visualization framework that integrates volumetric MRI data with cellular-level images.

“By establishing precise spatial correspondence across these modalities, the atlas enables a seamless transition from gross brain structures in the MRI to cellular-level features. We envision that these maps and atlases will have significant implications for neuroscience and neuromedicine,” he said.

Also read: India AI Summit: Union Health Minister Nadda Launches SAHI And BODH Initiatives To Boost AI In Healthcare

What Is ANCHOR?

The human brainstem contains more than 200 nuclei and fiber tracts and plays a vital role in regulating essential body functions.

ANCHOR is an online platform featuring more than 800 serial histological sections stained for Nissl and seven immunochemical (IHC) markers from three human brainstems representing different stages of life:

• 25 fetal gestational weeks
• 9 years old
• 54 years old

The atlas also describes catecholaminergic groups across all three age groups, identifies the protoplasmic commissural dendrites of the hypoglossal nucleus, and describes the pretectal nuclei in the fetal brainstem.

Read More:79th World Health Assembly: India Created Over 880 Million Digital Health IDs, Says J P Nadda

Integrated Online Viewer

ANCHOR includes an online viewer that integrates:

• Magnetic resonance imaging (MRI)
• Block-face imaging
• Nissl-stained serial sections
• IHC-stained serial sections
• 3D reconstruction of the entire brainstem.

The National Institute of Virology (NIV) in Pune has confirmed Nipah virus infection in a 43-year-old man from Ramanattukara in Kerala's Kozhikode district.

The patient, who was earlier shifted from a private hospital to a dedicated Nipah isolation facility at Kozhikode Government Medical College Hospital, remains in critical condition and is currently on ventilator support under the close supervision of a team of specialists, as per officials.

The patient was initially transferred to the Medical College Hospital after testing positive in a preliminary examination conducted at the Virus Research and Diagnostic Laboratory (VRDL). Following preliminary test results that suggested Nipah infection, the Kerala Health Department swung into action and intensified surveillance and containment measures in Kozhikode district.

77 Contacts Identified Through Tracing Efforts

After confirmation from NIV Pune, health authorities launched extensive contact-tracing efforts. District officials have identified 77 people who may have been exposed to the patient through contact tracing:

Notably, the patient's immediate family members—including his wife, two children, father, and mother—have been placed under quarantine.

In addition, two staff members of a private hospital in Kozhikode who interacted with the patient during earlier treatment have also been advised to remain in quarantine. Samples from five primary contacts have been sent to the VRDL laboratory for testing, as per media reports.

Also read: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

No Need for Containment Zone Yet, Says Minister

As per District Collector M.S. Madhavikutty, none of the identified contacts are currently showing symptoms and there is no immediate need to declare a containment zone.

Health Minister K. Muraleedharan also stated that the current situation does not warrant the declaration of a containment zone in Ramanattukara.

"The 15 priority contacts have been advised to remain in quarantine. A rapid response team meeting was held to ensure the availability of PPE kits and gloves. There is no shortage of medicines, and additional supplies will arrive from Chennai," the minister said.

Officials Probing Possible Source of Infection

The patient's initial symptoms included a high fever about a week ago and was later hospitalized with symptoms suggestive of encephalitis. But as his condition worsened, doctors tested for Nipah infection, which turned positive.

He is likely to have been exposed to the virus while cleaning an old godown in Puthukad, Malappuram district, reportedly connected to his soap manufacturing business.

Another likely source of infection is a chikoo tree located on the patient's property, where officials have reportedly observed the presence of bats and bird droppings.

"Anyone developing fever should voluntarily isolate themselves, wear a mask, and avoid close contact with others. However, making masks mandatory for the public is not being considered at present, as the situation does not require such a measure," Madhavikutty told reporters.

This is the 11th Nipah outbreak reported in Kerala since the virus was first detected in the state in 2018.

What Is Nipah Virus?

According to the World Health Organization, Nipah virus is a zoonotic disease, meaning it can spread from animals to humans. It can also be transmitted through contaminated food and, in some cases, directly from person to person.

In humans, infection can range from asymptomatic illness to severe respiratory disease and fatal encephalitis (brain inflammation). The virus can also infect animals such as pigs, causing significant economic losses for farmers.

Although outbreaks have been limited mainly to parts of Asia, the virus is known for its high fatality rate and potential to cause severe disease.

Symptoms of Nipah Virus Infection

Common symptoms include:

• Fever
• Headache
• Breathing difficulties
• Cough and sore throat
• Diarrhea
• Vomiting
• Muscle pain
• Severe weakness
• Dizziness
• Altered consciousness in severe cases
• Encephalitis (brain inflammation)

Why Is Nipah a Concern?

Nipah virus is considered a major public health threat because of:

• Its high mortality rate
• The ability to spread through close contact
• The absence of a specific antiviral treatment
• The lack of an approved vaccine for widespread use

People who survive Ebola virus disease (EVD) may continue to experience memory loss, irritability, and difficulty concentrating for more than seven years after recovering from the infection, according to a new study led by researchers at the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health (NIH).

The findings come as Ebola outbreaks continue in the Democratic Republic of Congo and Uganda, where confirmed cases have surpassed 650 and more than 130 deaths have been reported.

Long-Term Neurological Problems

The NIH partnered with Liberia's Ministry of Health to study the long-term effects of the disease during the 2014–2016 Ebola epidemic in West Africa, which caused more than 28,000 infections and over 11,000 deaths across Liberia, Guinea, and Sierra Leone.

Researchers evaluated 148 adult Ebola survivors and 81 uninfected close contacts who served as a comparison group. The results revealed that many people experienced significant neurological symptoms during the acute phase of the illness, some of which continued for seven long years.

During infection, survivors commonly reported headaches, altered mental status, and stroke-like symptoms. Long-term complications affected the brain and nervous system and included cognitive dysfunction, persistent headaches, sleep disturbances, depression, sexual dysfunction, tremors, fatigue, cranial nerve abnormalities, and abnormal sensations.

The researchers also found that headaches and neurological abnormalities remained more common among Ebola survivors than in people who had not been infected.

"Over time, survivors' symptoms and neurological examinations improved; however, more than 7 years later, a significant proportion continue to endorse memory loss," the researchers wrote in the study, published in JAMA Neurology.

Similarities to Long COVID

Also read: WHO Says Ebola Fight Is Catching Up; Expert Explains Science Behind Patient Recoveries

The study noted that many participants experienced symptoms similar to those seen in other post-infection conditions, including Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). These symptoms included headaches, memory loss, fatigue, and difficulty concentrating.

"This suggests possible shared pathophysiology, including persistent viral antigen or immune dysregulation," the researchers said.

However, the authors pointed out some important differences. While Long COVID and ME/CFS are often associated with autonomic nervous system dysfunction, such problems were not clearly identified among Ebola survivors, although dizziness and light-headedness were common.

How Does Ebola Affect the Brain?

The exact cause of long-term neurological problems after Ebola infection remains unclear. The researchers explained that during the acute illness, brain-related symptoms may be due to widespread inflammation, electrolyte imbalances, low blood pressure, blood-clotting abnormalities, or direct infection of the brain and nervous system by the virus.

On the other hand, long-term neurological issues may stem from persistent immune system changes, prolonged recovery from severe illness, or lingering viral material in the body.

Need For Continued Mental Health Care

Read More: Ebola Bundibugyo Outbreak: UK Scientists Identify 23 Unique Mutations

The researchers emphasized that neurological care should be a priority for clinicians treating Ebola survivors.

"Survivors experienced headaches, memory loss, and fatigue that may significantly impact quality of life," the authors wrote.

They noted that headaches often respond to standard preventive treatments, but survivors should continue to be monitored because of the rare risk of Ebola-related relapse in the central nervous system.

The study also found that many survivors experienced symptoms of depression, including suicidal thoughts. Because symptoms such as headaches, memory problems, concentration difficulties, and sleep disturbances can overlap with psychiatric disorders, the researchers stressed the importance of mental health evaluation and care.

Fortunately, many of these symptoms appear to improve or resolve over time with appropriate treatment and support.

Will Bundibugyo Survivors Face Lasting Brain Issues?

The current Ebola outbreak is caused by the Bundibugyo strain, which differs from the strain responsible for the 2014–2016 West African epidemic. Unlike the Zaire strain, there are currently no approved vaccines or antiviral treatments specifically for Bundibugyo Ebola, although some patients have recovered.

Researchers believe many of the long-term neurological effects observed in survivors of the West African outbreak could also occur in Bundibugyo survivors.